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The release of biologically active interleukin 6 (IL-6) frequently
occurs in human glioblastomas, the most malignant brain tumours
(Van Meir et al, 1990). In our previous study on a large series of 59
gliomas, we have demonstrated a strong association between the
aggressiveness of glial tumours and degree of IL-6 expression at
the RNA level (Rolhion et al, 2001). As IL-6 has properties of a
growth factor for tumour cells (Goswami et al, 1998) and is able to
block apoptosis induced by various chemotherapeutic compounds
(Borsellino et al, 1995) or reactive oxygen species (Miwa et al,
2000), the expression of the IL-6 gene may be one of the most
important factors contributing to the growth and survival of
glioblastoma cells in patients under radiotherapy and chemo-
therapy. 
The mechanism underlying the IL-6 upregulation in glioblas-
toma still remains unclear. The results of molecular cytogenetics in
glioblastoma point to frequent gains of chromosome 7 and ampli-
fication events on 7p (Weber et al, 1996). Since the IL-6 gene is
located on 7p21, the up-regulation of IL-6 expression in tumour
cells could be mediated by amplification of the gene. In order to
test this hypothesis, we determined the number of IL-6 gene copies
and IL-6 mRNA levels in glioblastoma cell lines and primary cells
using quantitative PCR assays. 
MATERIAL AND METHODS 
Tumour material 
Five glioblastoma cell lines including SF763 and SF767 (Joy et al,
1997), U87 and U251 (van Meir et al, 1994) and G5 (Buronfosse
et al, 1994) were used in this study. In addition, five samples of
primary tumour cells were obtained from patients with glioblas-
toma who underwent surgery. 
DNA and RNA extraction, cDNA preparation 
DNA and total RNAs were extracted using Trizol® reagent
(GIBCO/BRL, Grand Island, NY), according to the manufac-
turer’s instructions. Reverse transcription of RNA was performed
as described elsewhere (Rolhion et al, 1999). 
Competitive IL-6 gene dosage assay 
The IL-6 competitor was produced from normal human genomic
DNA using the PCR amplification method with a composite
primer (Celi et al, 1993). The conventional and composite IL-6
primers were derived from the IL-6 gene sequence (Yasukawak
et al, 1987) as follows: ILF, 5′ -AATTCGGTACATCCTCGACGG-
3′ (forward); ILR, 5′ -GGGCATGGATTTCAGACCC-3′ (reverse);
ILAILR, 5′ -GGGCATGGATTTCAGACCCCAGTCTAG-
GTCGTTGGCCTCA-3′ (composite primer). Schematic diagram
illustrating the generation of the competitor is presented in Figure
1A. Constant amounts of target DNA and serially diluted
competitor were co-amplified using the ILF/ILR primers. After the
separation on a 2%-agarose gel, the yields of amplified competitor
and target products were analysed and quantified using the Imager
Gel Documentation System (Appligene Oncor, Illkirch, France).
The amount of IL-6 molecules in the sample per nanogram of
DNA was calculated from the equivalence point where the amount
of amplified target was equal to the amount of amplified IL-6
competitor (Figure 1B). The relative changes in the number of IL-
6 copies in tumour DNA were estimated in comparison with
normal human DNA used as a reference in each PCR experiment
(Figure 1C). 
Real-time PCR analysis of gene dosage 
We quantitated IL-6 gene dosage using real-time PCR in the
LightCycler system (Roche Diagnostics, Meylan, France). The
amplification of IL-6 gene was performed using ILF/ILR primers
and a DNA Master SYBRGreen I reagent set (Roche Diagnostics).
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In parallel in the same samples, we assessed the dosage of another
gene from chromosome 7, the cystic fibrosis transmembrane
conductance regulator (CFTR) gene located on 7q31.2. The ampli-
fication of CFTR gene was performed using the primers described
by Dean et al (1990). To provide a genomic reference point for
each sample, the copy number of beta-globin gene, which is
located on chromosome 11 (11p15.5), was determined. The region
11p15.5 has not been reported to be involved in chromosomal
gains and losses observed in human glioblastomas (Schlegel et al,
1996; Nishizaki et al, 1998). The sequences of beta globin gene-
specific primers were as follows: forward, 5′ -GGTTGGCCAATC-
TACTCCCAG-3′ ; reverse, 5′ -GCTCACTCAGTGTGGCAAAG-3′ .
For dosage analysis of each gene, calibration curves were constructed
with serial dilutions of purified specific PCR products which
contained known numbers of DNA molecules. The results of real-
time PCR were expressed as a ratio of the copy number determined
for the target gene (IL-6 or CFTR) to the copy number of the control
gene, beta globin. 
Semiquantitative RT-PCR for IL-6 mRNA with an
endogenous standard 
IL-6 mRNA levels were assessed using a semiquantitative RT-PCR
as described in details previously (Rolhion et al, 1999). In this
approach, the ratio expression rate (RER) of IL-6 to 
β 2-microglobulin genes was determined. 
Real-time RT-PCR for IL-6 mRNA 
To quantitate IL-6 mRNA, fluorescent TaqMan methodology and
ABl Prism 7700 Sequence Detection System (Perkin Elmer
Applied Biosystems, Courtaboeuf, France) were used. A relative
quantitation was made with the comparative threshold cycles (∆∆
CT) method (PE User Bulletin #2, 1997) where the amount of IL-6
target was normalized to an endogenous reference, the 18S rRNA
gene, and relative to a calibrator, the U251 glioblastoma cell line.
The following amplification primers and probes were used: IL-6
forward primer 5′ -TGAACTCCTTCTCCACAAGCG-3′ ; reverse
primer 5′ -TCTGAAGAGGTGAGTGGCTGTC-3′ and labelled
probe 5′ -TGGTGTTGCCTGCTGTCCCT-3′ ;  18S rRNA gene
forward primer 5′ -CGGCTACCACATCCAAGGAA-3′ , reverse
primer 5′ -GCTGGAATTACCGCGGCT-3′ and probe 5′ -TGCTG-
GCACCAGACTTGCCCT-3′ . 
RESULTS 
IL-6 gene dosage 
We first quantified the number of IL-6 gene copies in DNA samples
using competitive PCR. In 5 control human genomic DNA
samples, this method determined a mean number of 226 (± 45, SD)
IL-6 gene molecules/ng of DNA. In most DNA samples obtained
from glioblastoma cells, the dosage of IL-6 gene was found to be
elevated, varying between 335 to 1135 gene molecules/ng of DNA
(mean, 719 ± 295). The IL-6 gene copy-number ratio of tumour
DNA to normal DNA varied from 1.58 to 4.87 (Table 1). 
As the increase in IL-6 gene dosage was relatively low, we
developed a sensitive real-time PCR strategy to confirm the find-
ings of competitive PCR. The real-time PCR analysis demon-
strated levels of IL-6 gene over-representation that were similar to
those obtained with competitive PCR (Table 1). A highly signif-
icant correlation was found between the results of two methods
(r = 0.94, P < 0.001). Interestingly, according to the results of
both methods, IL-6 gene over-representation was higher in
primary glioblastoma cells than in cell lines. 
To investigate the possibility that the increased dosage of IL-6
gene on 7p was due to a gain of the whole chromosome 7, we
determined the dosage of CFTR gene located on chromosome 7q.
As shown in Figure 3, the dosage of CFTR gene in tumour DNA
was elevated approximately 1.6-fold in GBM1 and GBM3
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Figure 1 (A) Construction of the IL-6 DNA competitor. Note that the 3′ end
of the composite primer ILAILR (segment ILA) corresponds to the opposite
strand of the target sequence at a predetermined distance from the primer
ILF, and the 5′ end is identical to the sequence of the primer ILR, 
whose binding site is located 43 bp upstream from the segment ILR. 
(B) Co-amplification of serial dilutions of competitor with a constant amount
of normal human DNA using ILF/ILR primers, spanning exon 2/intron 2 of the
IL-6 gene. The number of competitor molecules added is shown above each
lane. Two amplification products are generated, one derived from the target
DNA (IL-6) and another one, 62 bp smaller, derived from the competitor
(COMP). The equivalence point, at which competitor and target bands would
have the same intensity, is indicated by an arrow. M, PCR markers
(Promega). (C) Quantitation of IL-6 gene copies present in control and
glioblastoma (SF763 cell line) DNA samples using competitive PCR. The
equivalence points between the competitor and sample bands corresponded
to 103.9 and 104.4 competitor molecules as determined by means of
densitometry. Compensation for the difference in size between the competitor
and sample bands was made by multiplying the number of competitor
molecules at equivalence point by 0.76. The amounts of DNA used for PCR
being known, the numbers of competitor molecules at equivalence point were
converted into the numbers of IL-6 molecules per ng DNA: 221 for normal
DNA sample and 633 for SF763 DNA sample. M, PCR markers (Promega) 520 A Tchirkov et al 
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tumours, and in U251 cell line, suggesting a trisomy 7; and 2.2-
fold in the GBM4 tumour, indicating either a tetrasomy 7 or a low-
level amplification involving 7q31.2 chromosomal region. The
SF763 cell line demonstrated an underrepresentation of CFTR
gene of about 50%. CFTR gene dosage was found to be identical to
that of normal DNA in the remaining primary tumours and cell
lines. Overall, the dosage of IL-6 gene was higher than that of
CFTR gene in most glioblastoma samples. 
Table 1 IL-6 gene dosage and mRNA level in glioblastoma cells. The data are presented as mean ± SD of experiments performed in
triplicate 
Glioblastoma 
Fold-increase in IL-6 gene dosage IL-6 mRNA level 
specimens
Competitive PCR  Real-time PCR  Relative expression rate  Real-time RT-PCR 
(tumour/normal DNA  (IL-6/beta globin copy- IL-6/β 2 microglobulin IL-6/18S (∆∆ CT) 
copy-number ratio) number ratio)
Primary cells 
GBM2 4.87 ± 0.13 4.29 ± 0.08 0.90 ± 0.07 14.95 ± 2.61 
GBM5 4.70 ± 0.17 4.89 ± 0.10 1.06 ± 0.10 60.50 ± 5.28 
GBM1 4.03 ± 0.27 3.99 ± 0.06 0.05* 0.04 ± 0.03 
GBM4 3.06 ± 0.10 3.19 ± 0.15 0.26 ± 0.05 0.12 ± 0.03 
GBM3 2.89 ± 0.10 3.31 ± 0.08 0.23 ± 0.06 0.59 ± 0.01 
Cell lines 
SF763 2.86 ± 0.11 2.90 ± 0.04 0.68 ± 0.09 8.14 ± 0.32 
U251 2.56 ± 0.04 3.14 ± 0.11 0.40 ± 0.004 1.00 ± 0.11** 
U87 1.96 ± 0.02 2.28 ± 0.12 0.86 ± 0.09 20.01 ± 3.43 
G5 1.58 ± 0.07 1.53 ± 0.05 0.75 ± 0.01 7.48 ± 3.45 
SF767 1.17 ± 0.08 1.23 ± 0.03 0.00 0.00 
*Weak IL-6 mRNA expression at the limit of detection; **U251 cells were used as a calibrator for IL-6 mRNA. 
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Figure 2 Amplification profiles for IL-6 and beta-globin genes obtained on
the LightCycler from equal amounts of glioblastoma tumour GBM5 and
normal DNA. The fluorescence (SYBR Green I) is depicted on the Y axis; 
X-axis shows the number of PCR cycles. Quantitation of copy numbers was
based on determination of the crossover point (CT), marking the cycle when
fluorescence of a given sample rose above the background level 
Figure 3 Fold-changes in the dosage of IL-6 gene (chromosome 7p) and
CFTR gene (7q) estimated in glioblastoma and normal DNA samples relative
to a reference gene, the beta-globin (chromosome 11p) IL-6 gene amplification and expression in glioblastomas 521
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IL-6 gene expression 
IL-6 expression at the RNA level was studied using two quantita-
tive RT-PCR-based methods (Table 1). The results of two tech-
niques, RER IL-6/β 2-microglobulin and real-time PCR, correlated
well (r = 0.98, P < 0.001, log values of real-time PCR data were
used). Furthermore, we have found, for the primary glioblastoma
tumours included in the present study, a good concordance
between RNA expression (RER IL-6/β 2-microglobulin) and
protein detection using semiquantitative IL-6 immunohistochem-
istry of neoplastic cells (Rolhion et al, 2001). Among primary
tumour samples, the highest levels of IL-6 expression were
detected in two samples, GBM2 and GBM5, that harboured the
highest IL-6 gene copy number. However, GBM1 tumour with a
4-fold overrepresentation of the IL-6 gene showed a weak expres-
sion of IL-6 mRNA. All but one tumour cell line showed substan-
tial levels of IL-6 mRNA (Figure 4). No IL-6 expression was
detected in the SF767 cells that had no IL-6 gene over-representation.
DISCUSSION 
The studies described in this paper were initiated in order to esti-
mate the number of IL-6 gene copies in primary cells and cell lines
derived from glioblastoma tumours, which frequently show IL-6
over-expression. Using competitive PCR, we found that the
number of IL-6 gene copies was increased 3- to 5-fold in 5 of 5
primary tumour samples and 1.5- to 3-fold in 4 of 5 glioblastoma
cell lines. This finding was confirmed by means of real-time PCR
which has been proven to be the most appropriate method for
detecting low-level (≤ 5-fold) gene amplifications (Bièche et al,
1998). The number of IL-6 gene copies as determined by both
methods matched very well. 
The overrepresentation of IL-6 gene sequences detected in our
series of glioblastomas most likely results from amplifications
involving the IL-6 gene locus on chromosome 7p21. This hypoth-
esis is supported by the observation that large amplicons on chro-
mosome 7p are present in approximately two-thirds of human
glioblastomas (Harada et al, 1998). It seems unlikely that the 3- to
5-fold increase in IL-6 gene dosage results from gains of the whole
chromosome 7. When the copy number of CFTR gene from chro-
mosome 7q was quantitated, a 1.5-fold increase as compared with
normal DNA was found in 3 cases, suggestive of trisomy 7, and a
2.2-fold increase only in 1 case. In most individual cases of
glioblastoma tumours and cell lines, the representation of IL-6 gene
DNA was obviously higher than that of CFTR gene. Although the
number of tumours analysed in our study was small, a high
frequency of IL-6 amplification – 9 out of 10 cases – suggests that
this genetic alteration may be a common feature in glioblastomas.
Amplification may be one of mechanisms mediating the
upregulation of IL-6 gene in glioblastomas. In our study, all
glioblastomas with amplified IL-6 gene expressed IL-6 mRNA.
Interestingly, a higher level of expression was found in tumours
with the highest gene copy number, as measured using two
different quantitative RT-PCR approaches. However, no clear
correlation could be discerned between IL-6 gene copy number
and IL-6 mRNA level in the whole series. Similar observation was
reported in breast tumours where MYC gene over-expression did
not correlate with DNA over-representation at the MYC locus
(Bièche et al, 1999). In the same way, MDM2 amplification and
overexpression did not correlate in adult soft tissue sarcoma
(Cordon-Cardo et al, 1994). The amplified genes may be
rearranged, like the EGFR gene in some glioblastoma tumours
(Ekstrand et al, 1992), and therefore may not be over-expressed.
These findings are consistent with the idea that not only the
increase in gene copy number itself but also changes in the
amplicon structure regulate the mRNA expression. 
Amplifications of several genes that are implicated in tumour
progression characterize glioblastomas (see for review Pathology
and Genetics of Tumours of the Nervous System, 2000). In tumour
cells, the amplicons containing EGFR, the gene the most
frequently amplified in glioblastomas (Canute et al, 1996), MET
(Fischer et al, 1995), c-MYC (Trent et al, 1986) and GLI (Xiao
et al, 1994) are located on double minute chromosomes (DMs).
These observations indicate that glioblastomas are susceptible to
gene amplifications manifesting as DMs. It is reasonable to
hypothesize that IL-6 amplicons are present in glioblastomas on
DMs. Indirect evidence for this localization may be provided by
the observation that primary tumour cells revealed higher levels of
IL-6 amplification than glioblastoma cell lines. As DMs are
randomly distributed to daughter cells during division, the change
in selection pressure when glioblastoma cells are grown in vitro
could reduce the frequency of DMs. We envisage studies using
fluorescence in situ hybridization (FISH) with IL-6-gene specific
molecular probes to confirm and examine IL-6 gene amplification
and its localization. The cell-by-cell analysis using FISH is the
most suitable method for this purpose, as amplifications on chro-
mosome 7p in glioblastomas are intratumorally heterogeneous and
in some tumours only found in single areas (Jung et al, 1999). 
IL-6 expression appears to be a marker of glioma malignancy
that is strongly correlated with tumour aggressiveness and could
be considered as a potential therapeutic target. In this regard,
further studies of IL-6 gene amplification and amplicon localiza-
tion on large series of primary tumours are essential to gain infor-
mation that may be of value for new therapeutic investigations. 
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